These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 23946523)

  • 1. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.
    Brown-Elliott BA; Iakhiaeva E; Griffith DE; Woods GL; Stout JE; Wolfe CR; Turenne CY; Wallace RJ
    J Clin Microbiol; 2013 Oct; 51(10):3389-94. PubMed ID: 23946523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates.
    Kim SY; Kim DH; Moon SM; Song JY; Huh HJ; Lee NY; Shin SJ; Koh WJ; Jhun BW
    Sci Rep; 2021 Mar; 11(1):6108. PubMed ID: 33731862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex.
    Brown-Elliott BA; Philley JV; Griffith DE; Thakkar F; Wallace RJ
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
    Fröberg G; Maurer FP; Chryssanthou E; Fernström L; Benmansour H; Boarbi S; Mengshoel AT; Keller PM; Viveiros M; Machado D; Fitzgibbon MM; Mok S; Werngren J; Cirillo DM; Alcaide F; Hyyryläinen HL; Aubry A; Andres S; Nadarajan D; Svensson E; Turnidge J; Giske CG; Kahlmeter G; Cambau E; van Ingen J; Schön T;
    Clin Microbiol Infect; 2023 Jun; 29(6):758-764. PubMed ID: 36813087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex.
    Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K
    Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
    Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan.
    Yamaba Y; Ito Y; Suzuki K; Kikuchi T; Ogawa K; Fujiuchi S; Hasegawa N; Kurashima A; Higuchi T; Uchiya KI; Watanabe A; Niimi A
    J Infect Chemother; 2019 Dec; 25(12):995-1000. PubMed ID: 31239192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimicrobial susceptibility and genotyping of
    Wang SQ; Jiang GL; Wei GM; Huo FM; Dong LL; Zhao LP; Huang HR; Wang GR
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Jul; 41(7):539-543. PubMed ID: 29996350
    [No Abstract]   [Full Text] [Related]  

  • 9. Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand.
    Sirichoat A; Kaewprasert O; Hinwan Y; Faksri K
    PLoS One; 2023; 18(11):e0294677. PubMed ID: 37992075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex.
    Park B; Shim TS; Jo KW; Won EJ; Kim MN; Sung H
    Tuberculosis (Edinb); 2023 Dec; 143():102427. PubMed ID: 37918057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in drug susceptibility distribution and clinical characteristics between
    Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
    J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
    [No Abstract]   [Full Text] [Related]  

  • 12. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
    Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
    J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
    Huang CC; Wu MF; Chen HC; Huang WC
    J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China.
    Zhao X; Wang Y; Pang Y
    Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing minimum inhibitory concentrations of amikacin for pulmonary Mycobacterium avium complex disease: An analysis of culture media differences.
    Morita A; Namkoong H; Uwamino Y; Mitarai S; Aono A; Asakura T; Yagi K; Tanaka H; Azekawa S; Nakagawara K; Kaji M; Nagao G; Kamata H; Matsushita H; Fukunaga K; Hasegawa N
    J Infect Chemother; 2024 Feb; 30(2):159-163. PubMed ID: 37717608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
    Zheng HW; Pang Y; He GX; Song YY; Zhao YL
    Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterizations of clarithromycin-resistant Mycobacterium avium clinical isolates.
    Lee SH; Park YK; Kim CK; Kim HJ
    J Clin Lab Anal; 2011; 25(1):33-6. PubMed ID: 21254240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimum inhibitory concentrations of azithromycin in clinical isolates of
    Uwamino Y; Aoki W; Inose R; Kamoshita Y; Mikita K; Namkoong H; Nishimura T; Matsushita H; Hasegawa N
    Microbiol Spectr; 2024 Jun; 12(6):e0021824. PubMed ID: 38687080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.
    Schön T; Chryssanthou E
    Int J Infect Dis; 2017 Feb; 55():122-124. PubMed ID: 28069470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.